News

Celebrating Dr. Jessica L. Ables: A Leader in Psychiatry

Celebrating Dr. Jessica L. Ables: A Leader in Psychiatry

Acknowledging Dr. Jessica L. Ables' Professional Achievements

Renowned in her field, Dr. Jessica L. Ables, MD, PhD, has recently been celebrated for her impressive contributions to medicine and medical research. Her recognition as a Pinnacle Professional Member in The Inner Circle solidifies her status as a leader in psychiatry.

About Dr. Jessica L. Ables

Dr. Ables is a highly qualified board-certified psychiatrist and an Assistant Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai. Her specialization lies in treatment-resistant depression and mood disorders, particularly for patients with complex conditions that demand nuanced and individualized treatment strategies. She takes a holistic approach to patient care, ensuring that each treatment plan is tailored to meet both the biological and psychological needs of her patients. This personalized focus fosters long-term recovery and enhances the quality of life for those she treats.

Research Contributions and Focus Areas

In addition to her clinical work, Dr. Ables is deeply involved in research that has significantly advanced the field of psychiatry. She investigates various key areas, including the mechanisms underlying substance abuse, the impact of diabetes on brain function, and the design of therapeutic protocols for ketamine treatment. This unique blend of clinical expertise and laboratory research propels the development of neuroscience-driven and biologically informed psychiatric treatments.

Academic Background and Career Path

Dr. Ables holds a Bachelor of Science degree in chemistry, graduating cum laude from Southwestern University in Texas. Her academic journey continued as she enrolled in the Medical Scientist Training Program at the University of Texas Southwestern Medical Center, where she earned a combined MD and PhD in integrative biology with a concentration in neuroscience. Following this, she transferred to the Icahn School of Medicine at Mount Sinai to complete her last two years of training. Her career progressed with a postdoctoral fellowship in molecular neuroscience and addiction at Rockefeller University and a psychiatric residency at her current institution, where she now serves on the faculty.

Within the Icahn School of Medicine at Mount Sinai, Dr. Ables holds various prestigious positions, including roles in the Friedman Brain Institute and the Diabetes Obesity and Metabolism Institute. Her work reflects a commitment to interdisciplinary research and collaboration across various domains in medicine.

Professional Affiliations and Contributions

Dr. Ables maintains active membership in numerous leading medical and scientific organizations such as the Society for Neuroscience and the American Psychiatric Association. Her dedication extends beyond research and clinical practice—she serves on the MSTP admissions committee and participates in clinical trials at the Dennis S. Charney, MD Depression and Anxiety Center. These roles underscore her commitment to education and the betterment of public health.

Awards and Recognition

Recognized for her outstanding contributions, Dr. Ables has received several prestigious accolades, including the NARSAD Young Investigator Award from the Brain and Behavior Research Foundation and a Pathways Award from Alkermes Inc. Her research endeavors have also garnered funding support from notable entities, aiding her mission to enhance psychiatric care.

Future Aspirations and Impact

Looking ahead, Dr. Ables is determined to further bridge the gap between laboratory discoveries and clinical application. She believes that advances in neuroscience hold the potential to revolutionize mental health care, offering new avenues of hope for those affected by severe psychiatric disorders. Her ongoing commitment is to facilitate new treatments that can positively impact patients and their families.

Frequently Asked Questions

What is Dr. Jessica L. Ables known for?

Dr. Ables is known for her contributions to the fields of psychiatry and neuroscience, specifically her work on treatment-resistant depression and mood disorders.

Where does Dr. Ables work?

She is an Assistant Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai.

What types of research does Dr. Ables conduct?

Her research focuses on substance abuse mechanisms, the effects of diabetes on the brain, and developing therapeutic protocols for ketamine treatment.

What awards has Dr. Ables received?

Dr. Ables has received the NARSAD Young Investigator Award and a Pathways Award from Alkermes Inc.

What are Dr. Ables' future goals?

She aims to advance discoveries from research into clinical trials to foster new treatments that benefit patients directly.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 32

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 127

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 41

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 253

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 277

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 20

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 80

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 237

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading

Top 5 Most Recently Viewed Articles

Novotech Unveils Insights on Triple-Negative Breast Cancer Trials

Updated Category News Views 148

Insights into Triple-Negative Breast Cancer Clinical Trials Novotech, a global leader in full-service clinical Contract Research Organization (CRO), has published a significant report studying the global landscape of clinical trials and drug development for Triple-Negative Breast Cancer (TNBC). This comprehensive document sheds light on major advancements in therapeutic...

Continue Reading
Direct Digital's Bold Exit: Delists from Nasdaq

Updated Category News Views 32

Delisting Drama: Navigating Direct Digital's Market Move Looks like Direct Digital Holdings is getting caught up in the whirlwind of delisting and deregistering its Class A common stock from the Nasdaq. This move isn't just about hopping off a big exchange—it’s a whole new set of dance steps in the market. Timing and Mechanics of the Departure They’ve set their...

Continue Reading
Analyzing KULR Technology Group's Rising Short Interest Trends

Updated Category News Views 552

KULR Technology Group's Short Interest Overview KULR Technology Group's (NYSE: KULR) short percent of float has seen a notable rise of 27.11% since the last report. Recent disclosures indicate that there are approximately 18.31 million shares sold short, equating to about 8.44% of all regular shares currently available for trading. Given the volume at which KULR trades,...

Continue Reading
Cantaloupe, Inc. Introduces Next-Gen Smart Store Solutions

Updated Category News Views 291

Revolutionizing Retail with Smart Store Technology Cantaloupe, Inc. (Nasdaq: CTLP), recognized globally for its cutting-edge technology solutions in self-service commerce, has recently unveiled its innovative Smart Store Series. This pioneering series includes the Cantaloupe Smart Store 600 and 700 models, which aim to transform the retail landscape for food and beverage...

Continue Reading
New Leadership Boosts Compass Lexecon's Antitrust Division

Updated Category News Views 176

Strategic Growth at Compass Lexecon Compass Lexecon, a key player in economic consulting, recently announced the significant appointments of Dr. Jeremy Verlinda as Executive Vice President and Mr. Ahsan Kirmani as Senior Vice President. This move is a testament to the firm's commitment to expanding its expertise, particularly in antitrust and financial consulting. New...

Continue Reading